ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of two abstracts for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback